Bloomberg reported Novartis will end development of pelacarsen for atherosclerotic cardiovascular disease after its September 2026 trial failure, while continuing one calcific aortic valve stenosis study.
Health / Business
Add as a preferred source on GoogleNovartis to End Pelacarsen Development for Atherosclerotic Cardiovascular Disease
Ionis Pharmaceuticals discovered pelacarsen. Novartis said its Phase 3 Lp(a)HORIZON trial missed its primary endpoint in September 2026.
Updated 1 min read
Related articles
Health
BioArctic Says Novartis Ends Deal With Up to US$772 Million in Potential Milestones
BioArctic will keep its US$30 million upfront payment and record the unrecognized portion as revenue in 2026.
Technology
Companies Report AI Gains, but Most Do Not Quantify the Payoff
Banco Santander reported €194 million in AI-related business value for the first nine months of 2026. Meta and other companies described AI-linked gains without quantifying their contribution to broader results.
Health
Novartis’ MS Candidate Meets Trial Goals as Entresto Faces Generic Competition
Remibrutinib cut relapse rates by 35.2% and 31.2% in two studies, below the 45% to 60% analysts had expected, Reuters reported.